CNS Pharmaceuticals (CNSP) Income from Continuing Operations (2018 - 2025)

CNS Pharmaceuticals (CNSP) has 8 years of Income from Continuing Operations data on file, last reported at 5988847.0 in Q4 2025.

• Quarterly Income from Continuing Operations fell 87.13% year-over-year to 5988847.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 16001789.0 (down 7.28% YoY) and the FY2025 annual result came in at 34810559.0, down 15.25% from the prior year.
• Income from Continuing Operations eased to 5988847.0 in Q4 2025, from 3255504.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 2413570.0 in Q2 2025 to a low of 5988847.0 in Q4 2025.
• A 5-year average of 3980641.5 and a median of 3713769.0 in 2021 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2021 — Income from Continuing Operations slumped 89.67% — and 2025, when it surged 42.19%.
• Tracing CNSP's Income from Continuing Operations over 5 years: stood at 3254104.0 in 2021, then plunged by 57.89% to 5137918.0 in 2022, then declined by 4.76% to 5382252.0 in 2023, then surged by 40.54% to 3200301.0 in 2024, then sank by 87.13% to 5988847.0 in 2025.
• The last three Income from Continuing Operations figures came in at 5988847.0 (Q4 2025), 3255504.0 (Q3 2025), and 2413570.0 (Q2 2025), per Business Quant data.